ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions ('Dyadic'), a global ...

ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company ...

An experimental gene-editing therapy developed by Crispr Therapeutics is showing promise for treating heart disease.

The patient who was hospitalized after receiving Intellia Therapeutics’ CRISPR therapy nex-z has died. | The patient who was ...

A CRISPR-based gene editing therapy dramatically reduced levels of LDL cholesterol and triglycerides in patients with heart ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...

A new West Coast biotech has emerged into the busy in vivo cell therapy space, this time with the backing of Nobel Prize-winning CRISPR pioneer Jennifer Doudna, Ph.D. Azalea Therapeutics has bloomed ...

Morning! Lots in biotech today…. New priority review vouchers from the FDA, Mark Cuban rolls out a biosimilar deal, and a ...

Phase 1 data showed CRISPR’s one-time treatment, CTX310, produced sharp, dose-dependent reductions in triglycerides and LDL cholesterol with a strong safety profile. ・The company plans to advance the ...

CRISPR Therapeutics (CRSP) posts new data from an early stage trial for CTX310, an in vivo gene editing therapy for heart ...

Learn more about whether BioMarin Pharmaceutical Inc. or CRISPR Therapeutics AG is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The convergence of AI, quantum computing, and biosciences is propelling the global healthcare industry into a new era - now projected to surpass US$1.7 trillion in AI-driven biotech spending by 2025, ...